Inclusion Criteria:

- Adult patients at least 18 years of age.

- All patients must have an advanced solid tumor that has failed standard therapy or
for which no standard therapy exists.

- Histological or cytological diagnosis of a malignant solid tumor.

- Measurable or non-measurable disease.

- Any chemotherapy, radiotherapy, or major surgery at least 4 weeks prior to study
entry (6 weeks for nitrosoureas or mitomycin C). Patients must have recovered from
the toxic effects of any prior therapy.

- Karnofsky performance status index greater than or equal to 80.

- Must have adequate organ and immune system function according to the study design,
obtained less than or equal to 7-days prior to treatment with NM-3.

- Female patients of childbearing potential must have a negative serum pregnancy test
within 7 days of study enrollment. Men and women with reproductive potential must
use an effective contraceptive method while enrolled in this study and for 3 months
after the patient has completed study.

- Patient must be able to swallow.

- Signed, written informed consent from patient or guardian.

- Estimated life expectancy of at least 12 weeks.

Exclusion Criteria:

- Known sensitivity to study drug or its analogs.

- Treatment with any investigational therapy within the preceding 4 weeks.

- Patients with hematological malignancies including leukemia, lymphoma, or multiple
myeloma.

- Active and uncontrolled infection.

- Psychiatric disorders, alcohol or chemical abuse that would interfere with consent or
follow-up.

- Uncontrolled congestive heart failure or angina.

- Pregnancy or lactation.

- Any other severe concurrent disease, which as judged by the investigator, would make
the patient inappropriate for entry into this study.

- Patients with active gastrointestinal bleeding or ulceration, unhealed wounds or
active thrombosis.

- Patients who are on anticoagulant therapy or taking aspirin, nonsteroidal
anti-inflammatory drugs, unfractionated heparin, low molecular weight heparin,
danaproid, thrombolytic agents, anti-platelet antibodies, glycoprotein IIb, IIIa
antagonists, H2 blockers, or proton pump inhibitors.

- Brain or leptomeningeal metastases.

- Patients known to be HIV positive or who have an AIDS-related illness.

- Patients with a history of gastrointestinal bleeding from varices, arteriovenous
malformations, Osler Weber Rendu syndrome, polyps, prior surgery, or gastric
ulcerations. Patients who had bleeding not associated with a coagulopathy after
surgery or gastric ulceration and who have no further bleeding or recurrence of their
ulcers for more than one year are eligible for this study.

- Patients with a total accumulated doxorubicin or equivalent dose over 450 mg/m2.

- Patients with more than 1 risk factor, where a risk factor is defined as any one of
the following (1-7):1. prior anthracyclines larger than 300 mg/m2 doxorubicin
equivalent.2.mediastinum/left breast irradiation. 3.history of arterial hypertension
(systolic blood pressure greater than 140 or diastolic blood pressure greater than
90, or receiving anti-hypertensive treatment).4. obesity (body mass index
(BMI)[30]).5. diabetes mellitus (fasting plasma glucose level greater than 126 mg/dL
American Diabetes Association (ADA) guidelines).6. smoking (any smoking in the month
prior to study entry).7. hypercholesterolemia (greater than 240 mg/dL).